SCHERIPROCT SUPPOSITORIES SUPPOSITORY

Country: South Africa

Language: English

Source: South African Health Products Regulatory Authority (SAHPRA)

Available from:

Adcock Ingram Limited

Dosage:

See ingredients

Pharmaceutical form:

SUPPOSITORY

Composition:

EACH SUPPOSITORY CONTAINS CINCHOCAINE HYDROCHLORIDE 1,0 mg PREDNISOLONE HEXANOATE 1,3 mg

Authorization status:

Registered

Authorization date:

2000-03-08

Patient Information leaflet

19 April 2022
SIGNED:
S.R
APPROVED PATIENT INFORMATION LEAFLET FOR [SCHERIPROCT SUPPOSITORIES]
SCHEDULING STATUS
S4
SCHERIPROCT SUPPOSITORIES
(1,3 mg Prednisolone hexanoate / 1,0 mg cinchocaine hydrochloride per
1 g)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING
SCHERIPROCT
SUPPOSITORIES
•
Keep this leaflet. You may need to read it again.
•
If you have further questions, please ask your doctor, pharmacist,
nurse or other health care provider.
•
SHERIPROCT SUPPOSITORIES
has been prescribed for you
personally and you should not share your medicine with other
people. It
may harm them, even if their symptoms are the same as
yours.
WHAT IS IN THIS LEAFLET
1. What
SCHERIPROCT SUPPOSITORIES
is and what it is used for
2. What you need to know before you use
SCHERIPROCT SUPPOSITORIES
3. How to use
SCHERIPROCT SUPPOSITORIES
4. Possible side effects
5. How to store
SCHERIPROCT SUPPOSITORIES
6. Contents of the pack and other information
19 April 2022
SIGNED:
S.R
1. WHAT SCHERIPROCT SUPPOSITORIES IS AND WHAT IT IS USED FOR
SCHERIPROCT SUPPOSITORIES
contains a substance called prednisolone, which reduces
inflammation and also a local anaesthetic (chinchocaine) which
relieves pain.
This medicine is used for the short term (usually 5 – 7 days)
symptomatic relief of peri-anal (located around
the anus, the opening of the rectum to the outside of the body)
discomfort, inflammation and itching caused
by thrombosed haemorrhoids (piles), anal fissure (a small tear in the
thin, moist tissue (mucosa) that lines
the anus) and pruritus ani (irritating, itchy sensation around the
anus).
2. WHAT YOU NEED TO KNOW BEFORE YOU USE SCHERIPROCT SUPPOSITORIES
DO NOT USE SCHERIPROCT SUPPOSITORIES
•
if you are hypersensitive (allergic) to (prednisolone heaxanoate or
chinchocaine hydrochloride)
or any of the other ingredients of
SCHERIPROCT SUPPOSITORIES
(listed in section 6).
•
if you have a viral infection (e.g. herpes, shingles, chicken-pox).
•
if you have any bacterial or fungal infections of the skin or
elsewhere for wh

Summary of Product characteristics

19 April 2022
SIGNED:
S.R
APPROVED PROFESSIONAL INFORMATION FOR SCHERIPROCT SUPPOSITORIES
SCHEDULING STATUS
S4
1. NAME OF THE MEDICINE
SCHERIPROCT SUPPOSITORIES
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1 suppository contains prednisolone hexanoate 1,3 mg and cinchocaine
hydrochloride 1 mg.
For full list of excipients, see section 6.1.
_ _
3. PHARMACEUTICAL FORM
Yellowish-white suppositories without cosmetic defects
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Short term (5 – 7 days) symptomatic relief of perianal discomfort,
inflammation and itching caused by
thrombosed haemorrhoids, anal fissure and pruritus ani.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
The anal region should be cleaned thoroughly before using
SCHERIPROCT SUPPOSITORIES
, which is
best inserted after defaecation.
Unless otherwise prescribed by the doctor, generally insert one
suppository daily high into the rectum. If
symptoms are severe, insert one suppository two to three times on the
first day.
_ _
There is usually a rapid improvement, but this should not mislead one
into stopping treatment too
soon.
4.3 CONTRAINDICATIONS
•
Hypersensitivity to prednisolone hexanoate, cinchocaine hydrochloride
or to any of the other
excipients of
SCHERIPROCT SUPPOSITORIES
.
•
Viral infections, primary bacterial or fungal infections in the
treatment area.
•
Virus diseases (e.g. vaccinia, chickenpox).
•
Secondary infections of the skin in the absence of appropriate
anti-infective therapy.
•
Known sensitivity to local anaesthetics.
•
Corticosteroids have been shown to be teratogenic in animals
Corticosteroids have been shown to be teratogenic in animals following
dermal application. As
these agents are absorbed percutaneously, teratogenicity following
topical application cannot be
excluded. Therefore,
SCHERIPROCT SUPPOSITORIES
should not be used during pregnancy.
•
Tuberculous or syphilitic processes in the area to be treated
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
This product should not be used continuously for more than